article

1. Feasibility of using real-world data to emulate substance use disorder clinical trials: a cross-sectional study..  BMC medical research methodology.  24:-. 2024
2. Quantitative bias analysis methods for summary-level epidemiologic data in the peer-reviewed literature: a systematic review..  Journal of clinical epidemiology.  -. 2024
3. Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges..  European heart journal.  44:4220-4229. 2023
4. Medical Product Industry Ties to Patient Advocacy Organizations' Executive Leadership..  JAMA internal medicine.  183:1164-1166. 2023
5. Unique Device Identifiers for Medical Devices at 10 Years..  JAMA internal medicine.  183:1045-1046. 2023
6. Financial Conflicts of Interest in Public Comments on Medicare National Coverage Determinations of Medical Devices..  JAMA.  330:1094-1096. 2023
7. Clinical Phenotyping with an Outcomes-driven Mixture of Experts for Patient Matching and Risk Estimation..  ACM transactions on computing for healthcare.  4:1-18. 2023
8. US Postgraduate Trainee Racial, Ethnic, and Gender Representation and Faculty Compensation By Specialty..  JAMA.  330:872-874. 2023
9. Pain Management in Older Adults Before and During the First Year of COVID-19 Pandemic: Prevalence, Trends, and Correlates..  The journals of gerontology. Series A, Biological sciences and medical sciences.  78:1627-1640. 2023
10. Assessing the use of observational methods and real-world data to emulate ongoing randomized controlled trials..  Clinical trials (London, England).  20:689-698. 2023
11. Comparative effectiveness of second line glucose lowering drug treatments using real world data: emulation of a target trial..  BMJ medicine.  2:-. 2023
12. Clinical trial data sharing: a cross-sectional study of outcomes associated with two U.S. National Institutes of Health models..  Scientific data.  10:-. 2023
13. Press Releases of Drug-Related Randomized Trial Results Prior to Publication in High-Impact Journals: an Observational Study..  Journal of general internal medicine.  38:3107-3114. 2023
14. Approval of Drugs With Unmet Trial End Points-In Reply..  JAMA internal medicine.  183:889-890. 2023
15. Transparency of Results Reporting in Cancer Clinical Trials..  JAMA network open.  6:-. 2023
16. Use of Electronic Health Records to Characterize Patients with Uncontrolled Hypertension in Two Large Health System Networks..  medRxiv : the preprint server for health sciences.  2023
17. The Changing Medical Publishing Industry: Economics, Expansion, and Equity..  Journal of general internal medicine.  38:3242-3246. 2023
18. Therapeutic value of first versus supplemental indications of drugs in US and Europe (2011-20): retrospective cohort study..  BMJ (Clinical research ed.).  -. 2023
19. Association of Receipt of Paycheck Protection Program Loans With Staffing Patterns Among US Nursing Homes..  JAMA network open.  6:-. 2023
20. Availability of Unique Device Identifiers for Class I Medical Device Recalls From 2018 to 2022..  JAMA internal medicine.  183:735-737. 2023
21. Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review..  Journal of clinical epidemiology.  83-99. 2023
22. Extending the US Food and Drug Administration's Postmarket Authorities..  JAMA health forum.  4:-. 2023
23. Trends in the Use of Gabapentinoids and Opioids in the Postoperative Period Among Older Adults..  JAMA network open.  6:-. 2023
24. US Food and Drug Administration Review Time of Supplemental New Indication Approvals of Drugs and Biologics, 2017 to 2019..  JAMA network open.  6:-. 2023
25. Longitudinal Patterns in Testosterone Prescribing After US FDA Safety Communication in 2014..  Joint Commission journal on quality and patient safety.  49:458-466. 2023
26. Characterization of US Food and Drug Administration Class I Recalls from 2018 to 2022 for Moderate- and High-Risk Medical Devices: A Cross-Sectional Study..  Medical devices (Auckland, N.Z.).  111-122. 2023
27. US Orphan Drug Act..  BMJ (Clinical research ed.).  -. 2023
28. Challenges and solutions to advancing health equity with medical devices..  Nature biotechnology.  41:607-609. 2023
29. Physician responses to apple watch-detected irregular rhythm alerts..  American heart journal.  29-37. 2023
30. Trends in Spending and Claims for P2Y12 Inhibitors by Medicare and Medicaid From 2015 to 2020..  Journal of the American Heart Association.  12:-. 2023
31. Ensuring Public Trust in an Empowered FDA..  The New England journal of medicine.  388:1249-1251. 2023
32. US Food and Drug Administration Approval of Drugs Not Meeting Pivotal Trial Primary End Points, 2018-2021..  JAMA internal medicine.  183:376-380. 2023
33. Evidence of publication bias in multiple sclerosis clinical trials: a comparative analysis of published and unpublished studies registered in ClinicalTrials.gov..  Journal of neurology, neurosurgery, and psychiatry.  94:597-604. 2023
34. Integrating 4 Measures to Evaluate Physical Function in Patients with Cancer (In4M): Protocol for a prospective study..  medRxiv : the preprint server for health sciences.  2023
35. Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method..  American heart journal.  124-140. 2023
36. Using real-world data from health systems to evaluate the safety and effectiveness of a catheter to treat ischemic ventricular tachycardia..  Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing.  66:1817-1825. 2023
37. Implementing clinical trial data sharing requires training a new generation of biomedical researchers..  Nature medicine.  29:298-301. 2023
38. Exploring unique device identifier implementation and use for real-world evidence: a mixed-methods study with NESTcc health system network collaborators..  BMJ surgery, interventions, & health technologies.  5:-. 2023
39. Financial conflicts of interest among US physician authors of 2020 clinical practice guidelines: a cross-sectional study..  BMJ open.  13:-. 2023
40. Adding device identifiers to claims forms-a key step to advance medical device safety..  BMJ (Clinical research ed.).  -. 2023
41. Integrating real-world data to assess cardiac ablation device outcomes in a multicenter study using the OMOP common data model for regulatory decisions: implementation and evaluation..  JAMIA open.  6:-. 2023
42. Use of Recalled Devices in New Device Authorizations Under the US Food and Drug Administration's 510(k) Pathway and Risk of Subsequent Recalls..  JAMA.  329:136-143. 2023
43. Metrics, baseline scores, and a tool to improve sponsor performance on clinical trial diversity: retrospective cross sectional study..  BMJ medicine.  2:-. 2023
44. Differences In Debt Among Postgraduate Medical Residents By Self-Designated Race And Ethnicity, 2014-19..  Health affairs (Project Hope).  42:63-73. 2023
45. Primary care institutional characteristics associated with hypertension awareness, treatment, and control in the China PEACE-Million Persons Project and primary health-care survey: a cross-sectional study..  The Lancet. Global health.  11:e83-e94. 2023
46. The Philips Respironics Recall of Ventilators and Positive Airway Pressure Machines-Breakdowns in Medical Device Surveillance..  JAMA internal medicine.  183:5-8. 2023
47. Artificial Intelligence in Breast Cancer Screening: Evaluation of FDA Device Regulation and Future Recommendations..  JAMA internal medicine.  182:1306-1312. 2022
48. Comparison of Clinical Study Results Reported in medRxiv Preprints vs Peer-reviewed Journal Articles..  JAMA network open.  5:-. 2022
49. Assessment of Market-Level Information on Quality Using Hospital Care Compare..  Journal of general internal medicine.  38:1581-1583. 2022
50. Retracted papers originating from paper mills: cross sectional study..  BMJ (Clinical research ed.).  -. 2022
51. Population-Level Strategies for Nirmatrelvir/Ritonavir Prescribing-A Cost-effectiveness Analysis..  Open forum infectious diseases.  9:-. 2022
52. Consistency between trials presented at conferences, their subsequent publications and press releases..  BMJ evidence-based medicine.  28:95-102. 2022
53. US Post-Graduate Residency Competitiveness, Trainee Diversity, and Future Salary Among 12 Clinical Specialties..  Journal of general internal medicine.  38:1567-1569. 2022
54. Medicare's National Coverage Determination for Aducanumab - A One-Off or a Pragmatic Path Forward?.  The New England journal of medicine.  387:1539-1541. 2022
55. Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE..  BMJ open.  12:-. 2022
56. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study..  BMJ (Clinical research ed.).  -. 2022
57. Spontaneous reporting of post-market safety signals: what evidence should support regulatory action?.  BMJ (Clinical research ed.).  -. 2022
58. Analysis of Patient-Focused Information About Left Atrial Appendage Occlusion on US Hospital Web Pages..  JAMA internal medicine.  182:1226-9. 2022
59. Characteristics of Retracted Research Articles About COVID-19 vs Other Topics..  JAMA network open.  5:-. 2022
60. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study..  BMJ (Clinical research ed.).  -. 2022
61. Post-submission changes to prespecified statistical analysis plans..  BMJ (Clinical research ed.).  -. 2022
62. Vibration of effect in more than 16 000 pooled analyses of individual participant data from 12 randomised controlled trials comparing canagliflozin and placebo for type 2 diabetes mellitus: multiverse analysis..  BMJ medicine.  1:-. 2022
63. E.  BMJ open.  12:-. 2022
64. Public Misinformation and Science Communication in Times of Public Health Crises..  Clinical chemistry.  68:1008-1014. 2022
65. Acute pain pathways: protocol for a prospective cohort study..  BMJ open.  12:-. 2022
66. Medicare Coverage and Out-of-Pocket Costs of Quadruple Drug Therapy for Heart Failure..  Journal of the American College of Cardiology.  79:2516-2525. 2022
67. Medical Device User Fee Reauthorization - Back to Basics or Looking Ahead?.  The New England journal of medicine.  387:196-199. 2022
68. Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance..  JAMA internal medicine.  182:603-611. 2022
69. Generating evidence during a pandemic: what's reliable?.  BMJ (Clinical research ed.).  -. 2022
70. Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study..  BMJ (Clinical research ed.).  -. 2022
71. A Different Case of Penumbra-Reply: A Japanese Framework for Safe and Expedited Access to High-Risk Medical Devices..  JAMA internal medicine.  182:570-571. 2022
72. In Medicaid Managed Care Networks, Care Is Highly Concentrated Among A Small Percentage Of Physicians..  Health affairs (Project Hope).  41:760-768. 2022
73. Association Between Generic-to-Generic Levothyroxine Switching and Thyrotropin Levels Among US Adults..  JAMA internal medicine.  182:418-425. 2022
74. FDA Indication Extrapolations-Allowing Flexibility While Providing Greater Clarity..  JAMA network open.  5:-. 2022
75. A multicenter evaluation of computable phenotyping approaches for SARS-CoV-2 infection and COVID-19 hospitalizations..  NPJ digital medicine.  5:-. 2022
76. Sensible regulation and clinical implementation of clinical decision support software as a medical device..  BMJ (Clinical research ed.).  -. 2022
77. Rates of, and factors associated with, switching among generic levothyroxine preparations in commercially insured American adults..  Endocrine.  76:349-358. 2022
78. Assessment of Hypothetical Out-of-Pocket Costs of Guideline-Recommended Medications for the Treatment of Older Adults With Multiple Chronic Conditions, 2009 and 2019..  JAMA internal medicine.  182:185-195. 2022
79. Association Between Payments by Pharmaceutical Manufacturers and Prescribing Behavior in Rheumatology..  Mayo Clinic proceedings.  97:250-260. 2022
80. Association of Psychiatric Diagnoses and Medicaid Coverage with Length of Stay Among Inpatients Discharged to Skilled Nursing Facilities..  Journal of general internal medicine.  37:3070-3079. 2022
81. Payer-Negotiated Prices for Telemedicine Services..  Journal of general internal medicine.  37:3495-3497. 2022
82. Renewing the Call for Reforms to Medical Device Safety-The Case of Penumbra..  JAMA internal medicine.  182:59-65. 2022
83. Heart Watch Study: protocol for a pragmatic randomised controlled trial..  BMJ open.  11:-. 2021
84. Loneliness, sadness, and feelings of social disconnection in older adults during the COVID-19 pandemic..  Journal of the American Geriatrics Society.  70:329-340. 2021
85. Feasibility of using real-world data in the evaluation of cardiac ablation catheters: a test-case of the National Evaluation System for Health Technology Coordinating Center..  BMJ surgery, interventions, & health technologies.  3:-. 2021
86. Strengthening the FDA's Enforcement of ClinicalTrials.gov Reporting Requirements..  JAMA.  326:2131-2132. 2021
87. Association of Fluoroquinolone Prescribing Rates With Black Box Warnings from the US Food and Drug Administration..  JAMA network open.  4:-. 2021
88. Clinician Trends in Prescribing Direct Oral Anticoagulants for US Medicare Beneficiaries..  JAMA network open.  4:-. 2021
89. Registration, publication, and outcome reporting among pivotal clinical trials that supported FDA approval of high-risk cardiovascular devices before and after FDAAA..  Trials.  22:-. 2021
90. Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials..  JAMA network open.  4:-. 2021
91. Comparison of Duration of Postapproval vs Pivotal Trials for Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval, 2009-2018..  JAMA network open.  4:-. 2021
92. Feasibility of Using Real-world Data to Emulate Postapproval Confirmatory Clinical Trials of Therapeutic Agents Granted US Food and Drug Administration Accelerated Approval..  JAMA network open.  4:-. 2021
93. [Not Available]..  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.  193:E1616-1618. 2021
94. Clinical studies sponsored by digital health companies participating in the FDA's Precertification Pilot Program: A cross-sectional analysis..  Clinical trials (London, England).  19:119-122. 2021
95. Assessment of FDA Approval for New High-risk Therapeutic Devices Not Meeting Pivotal Study Primary End Points, 2016-2020..  JAMA internal medicine.  181:1409-1412. 2021
96. Fulfilling the Mandate of the US Food and Drug Administration's Accelerated Approval Pathway: The Need for Reforms..  JAMA internal medicine.  181:1275-1276. 2021
97. Levothyroxine Use in the United States, 2008-2018..  JAMA internal medicine.  181:1402-1405. 2021
98. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment..  JAMA network open.  4:-. 2021
99. Feasibility of capturing real-world data from health information technology systems at multiple centers to assess cardiac ablation device outcomes: A fit-for-purpose informatics analysis report..  Journal of the American Medical Informatics Association : JAMIA.  28:2241-2250. 2021
100. Optimizing the data available via Health Canada's clinical information portal..  CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.  193:E1305-E1306. 2021
101. Misreporting of Results of Research in Psychiatry..  Schizophrenia bulletin.  47:1254-1260. 2021
102. Uptake of evidence by physicians: De-adoption of erythropoiesis-stimulating agents after the TREAT trial..  BMC nephrology.  22:-. 2021
103. Characteristics of available studies and dissemination of research using major clinical data sharing platforms..  Clinical trials (London, England).  18:657-666. 2021
104. The Association Between History of Depression and Access to Care Among Medicare Beneficiaries During the COVID-19 Pandemic..  Journal of general internal medicine.  36:3778-3785. 2021
105. Second-Line Therapy for Type 2 Diabetes Management: The Treatment/Benefit Paradox of Cardiovascular and Kidney Comorbidities..  Diabetes care.  44:2302-11. 2021
106. Impact of SGLT2 inhibitors in comparison with DPP4 inhibitors on ascites and death in veterans with cirrhosis on metformin..  Diabetes, obesity & metabolism.  23:2402-2408. 2021
107. Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement..  JAMA.  326:257-265. 2021
108. Unplanned hospital visits after ambulatory surgical care..  PloS one.  16:-. 2021
109. Clinical trial transparency and data sharing among biopharmaceutical companies and the role of company size, location and product type: a cross-sectional descriptive analysis..  BMJ open.  11:-. 2021
110. Drug labeling changes and pediatric hematology/oncology prescribing: Measuring the impact of U.S. legislation..  Clinical trials (London, England).  18:732-740. 2021
111. Physical activity, patient-reported symptoms, and clinical events: Insights into postprocedural recovery from personal digital devices..  Cardiovascular digital health journal.  2:212-221. 2021
112. Future of covid-19 vaccine pricing: lessons from influenza..  BMJ (Clinical research ed.).  -. 2021
113. Characteristics of Preapproval and Postapproval Studies of Vaccines Granted Accelerated Approval by the US Food and Drug Administration..  Journal of general internal medicine.  36:3281-3284. 2021
114. Cardiovascular outcomes and rates of fractures and falls among patients with brand-name versus generic L-thyroxine use..  Endocrine.  74:592-602. 2021
115. Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021..  JAMA.  326:184-5. 2021
116. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019..  JAMA network open.  4:-. 2021
117. Direct-to-consumer personal genomic tests need better regulation..  Nature medicine.  27:940-943. 2021
118. Medicare beneficiaries' plans for the COVID-19 vaccine in Fall 2020, and why some planned to decline..  Journal of the American Geriatrics Society.  69:2434-2437. 2021
119. Accuracy of Computable Phenotyping Approaches for SARS-CoV-2 Infection and COVID-19 Hospitalizations from the Electronic Health Record..  medRxiv : the preprint server for health sciences.  2021
120. Evaluation of Drug Trials in High-, Middle-, and Low-Income Countries and Local Commercial Availability of Newly Approved Drugs..  JAMA network open.  4:-. 2021
121. Evaluation of Trials Comparing Single-Enantiomer Drugs to Their Racemic Precursors: A Systematic Review..  JAMA network open.  4:-. 2021
122. US Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018..  Clinical trials (London, England).  18:488-499. 2021
123. Covid-19, open science, and the CVD-COVID-UK initiative..  BMJ (Clinical research ed.).  -. 2021
124. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics..  JAMA network open.  4:-. 2021
125. Speed, Evidence, and Safety Characteristics of Vaccine Approvals by the US Food and Drug Administration..  JAMA internal medicine.  181:559-560. 2021
126. Leveraging Open Science to Accelerate Research..  The New England journal of medicine.  384:-. 2021
127. Medicare's New Device-Coverage Pathway - Breakthrough or Breakdown?.  The New England journal of medicine.  384:-. 2021
128. U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016..  Journal of general internal medicine.  37:495-498. 2021
129. Demographic Characteristics of Participants in Trials Essential to US Food and Drug Administration Vaccine Approvals, 2010-2020..  Journal of general internal medicine.  37:700-702. 2021
130. Assessment of Concordance and Discordance Among Clinical Studies Posted as Preprints and Subsequently Published in High-Impact Journals..  JAMA network open.  4:-. 2021
131. Effects of forced disruption in Medicaid managed care on children with asthma..  Health services research.  56:668-676. 2021
132. Age-Related Trajectories of Cardiovascular Risk and Use of Aspirin and Statin Among U.S. Adults Aged 50 or Older, 2011-2018..  Journal of the American Geriatrics Society.  69:1272-1282. 2021
133. Physician variation in the de-adoption of ineffective statin and fibrate therapy..  Health services research.  56:919-931. 2021
134. Characteristics and Reporting of Number Needed to Treat, Number Needed to Harm, and Absolute Risk Reduction in Controlled Clinical Trials, 2001-2019..  JAMA internal medicine.  181:282-284. 2021
135. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019..  JAMA network open.  4:-. 2021
136. Publishing at any cost: a cross-sectional study of the amount that medical researchers spend on open access publishing each year..  BMJ open.  11:-. 2021
137. Use of Mechanical Circulatory Support Devices Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock..  JAMA network open.  4:-. 2021
138. To Expand the Evidence Base About Harms from Tests and Treatments..  Journal of general internal medicine.  36:2105-2110. 2021
139. Trends in Within-Class Changes in US Average Wholesale Prices for Brand-Name Medications for Common Conditions From 2015 to 2020..  JAMA network open.  4:-. 2021
140. Transparency of Regulatory Data across the European Medicines Agency, Health Canada, and US Food and Drug Administration..  The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.  49:456-485. 2021
141. Catheter-related complications and mortality of atrial fibrillation ablation following introduction of contact force-sensing technology..  BMJ surgery, interventions, & health technologies.  2:-. 2020
142. Reporting of substance use treatment quality in United States adult drug courts..  The International journal on drug policy.  -. 2020
143. Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019..  JAMA internal medicine.  180:1701-1703. 2020
144. Submissions and Downloads of Preprints in the First Year of medRxiv..  JAMA.  324:1903-1905. 2020
145. Association Between Industry Payments to Physicians and Device Selection in ICD Implantation..  JAMA.  324:1755-1764. 2020
146. Mandatory Registration and Results Reporting of Real-World Evidence Studies of FDA-Regulated Medical Products..  Mayo Clinic proceedings.  95:2609-2611. 2020
147. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study..  BMJ (Clinical research ed.).  -. 2020
148. Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation..  Circulation. Cardiovascular quality and outcomes.  13:-. 2020
149. Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov..  JAMA psychiatry.  77:1081-1084. 2020
150. Transparency and Accountability of Medicaid Section 1115 Waiver Demonstration Programs Under the Affordable Care Act..  JAMA network open.  3:-. 2020
151. Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels..  JAMA network open.  3:-. 2020
152. Non-inferiority trials using a surrogate marker as the primary endpoint: An increasing phenotype in cardiovascular trials..  Clinical trials (London, England).  17:723-728. 2020
153. Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011..  JAMA network open.  3:-. 2020
154. Early experience with the FDA's Breakthrough Devices program..  Nature biotechnology.  38:933-938. 2020
155. Consistency of trial reporting between ClinicalTrials.gov and corresponding publications: one decade after FDAAA..  Trials.  21:-. 2020
156. On-Label and Off-Label Clinical Studies of FDA-Approved Ophthalmic Therapeutics..  Ophthalmology.  128:332-334. 2020
157. Assessment of Health Status and Barriers to Employment Among Medicaid Beneficiaries Not Meeting Work Requirements After Accounting for State Medical Frailty Exemptions..  JAMA internal medicine.  180:1008-1010. 2020
158. Assessment of Preprint Policies of Top-Ranked Clinical Journals..  JAMA network open.  3:-. 2020
159. Disagreements Within the US Food and Drug Administration Regarding Approval of Novel Therapeutic Agents, 2011-2015..  JAMA network open.  3:-. 2020
160. Gout Treatment in the USA from 2009 to 2016: A Repeated Cross-sectional Analysis..  Journal of general internal medicine.  36:1134-1136. 2020
161. Availability of Telemedicine Services Across Hospitals in the United States in 2018: A Cross-sectional Study..  Annals of internal medicine.  173:503-505. 2020
162. Patient and provider-level factors associated with changes in utilization of treatments in response to evidence on ineffectiveness or harm..  International journal of health economics and management.  20:299-317. 2020
163. Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform..  NPJ digital medicine.  -. 2020
164. Commentary on Bertagnolli et al.: Leveraging electronic health record data for clinical trials-a brave new world..  Clinical trials (London, England).  17:243-246. 2020
165. Evaluation of the Anticipated Burden of COVID-19 on Hospital-Based Healthcare Services Across the United States..  medRxiv : the preprint server for health sciences.  2020
166. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017..  JAMA network open.  3:-. 2020
167. Medicare Prescription Drug Plan Coverage of Hormone Therapies Used by Transgender Individuals..  LGBT health.  7:137-145. 2020
168. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017..  Journal of managed care & specialty pharmacy.  26:562-567. 2020
169. Vibration of effects in epidemiologic studies of alcohol consumption and breast cancer risk..  International journal of epidemiology.  49:608-618. 2020
170. Impact of left ventricular assist devices and heart transplants on acute myocardial infarction and heart failure mortality and readmission measures..  PloS one.  15:-. 2020
171. Time for NIH to lead on data sharing..  Science (New York, N.Y.).  367:1308-1309. 2020
172. Conflicts of Interest Among Authors of Published Cannabidiol Articles, 2014-2019..  Annals of internal medicine.  172:769-771. 2020
173. Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease..  BMC medical research methodology.  20:-. 2020
174. Medicare beneficiaries' out-of-pocket costs for commonly used generic drugs, 2009-2017..  The American journal of managed care.  26:112-117. 2020
175. Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock..  JAMA.  323:734-745. 2020
176. Exploring crowdfunding campaigns for abortion services..  Contraception.  102:18-22. 2020
177. Attribution of Adverse Events Following Coronary Stent Placement Identified Using Administrative Claims Data..  Journal of the American Heart Association.  9:-. 2020
178. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses..  BMJ (Clinical research ed.).  -. 2020
179. Clinical Outcomes With Beta-Blocker Use in Patients With Recent History of Myocardial Infarction..  The Canadian journal of cardiology.  36:1633-1640. 2020
180. Confidentiality Orders and Public Interest in Drug and Medical Device Litigation..  JAMA internal medicine.  180:292-299. 2020
181. Impact of US industry payment disclosure laws on payments to surgeons: a natural experiment..  Research integrity and peer review.  -. 2020
182. The Human Costs of Medicare Fraud and Abuse..  JAMA internal medicine.  180:-. 2020
183. The Promise of Big Data and Digital Solutions in Building a Cardiovascular Learning System: Opportunities and Barriers..  Methodist DeBakey cardiovascular journal.  16:212-219. 2020
184. Recent trends in use of inferior vena caval filters in US older adults with acute pulmonary embolism..  Thrombosis research.  78-79. 2019
185. Systematic overview of Freedom of Information Act requests to the Department of Health and Human Services from 2008 to 2017..  Research integrity and peer review.  -. 2019
186. Availability of Grocery Delivery to Food Deserts in States Participating in the Online Purchase Pilot..  JAMA network open.  2:-. 2019
187. Digital medicine systems: an evergreening strategy or an advance in medication management?.  BMJ evidence-based medicine.  24:203-204. 2019
188. The Supreme Court's Latest Ruling on Drug Liability and its Implications for Future Failure-to-Warn Litigation..  The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.  47:783-787. 2019
189. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement..  Annals of internal medicine.  172:35-45. 2019
190. The Predictive Approaches to Treatment effect Heterogeneity (PATH) Statement: Explanation and Elaboration..  Annals of internal medicine.  172:W1-W25. 2019
191. Prevalence and significance of race and ethnicity subgroup analyses in Cochrane intervention reviews..  Clinical trials (London, England).  17:231-234. 2019
192. Evidence Supporting US Food and Drug Administration Drug Safety Communications..  JAMA internal medicine.  179:-. 2019
193. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings..  Journal of managed care & specialty pharmacy.  25:1201-1217. 2019
194. Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies..  Journal of general internal medicine.  34:2319-2321. 2019
195. Accidental drug overdose deaths in Connecticut, 2012-2018: The rise of polysubstance detection?.  Drug and alcohol dependence.  -. 2019
196. Modernizing the FDA's 510(k) Pathway..  The New England journal of medicine.  381:1891-1893. 2019
197. Age-treatment subgroup analyses in Cochrane intervention reviews: a meta-epidemiological study..  BMC medicine.  17:-. 2019
198. Medicare Formulary Coverage of Brand-Name Drugs and Therapeutically Interchangeable Generics..  Journal of general internal medicine.  35:1928-1930. 2019
199. Home Health Care After Skilled Nursing Facility Discharge Following Heart Failure Hospitalization..  Journal of the American Geriatrics Society.  68:96-102. 2019
200. Adoption of New Glucose-Lowering Medications in the U.S.-The Case of SGLT2 Inhibitors: Nationwide Cohort Study..  Diabetes technology & therapeutics.  21:702-712. 2019
201. Characteristics of Recent Generic Drug Approvals by the US Food and Drug Administration..  JAMA network open.  2:-. 2019
202. Feasibility of Using Real-World Data to Replicate Clinical Trial Evidence..  JAMA network open.  2:-. 2019
203. Use of Mechanical Cardiopulmonary Resuscitation Devices for Out-of-Hospital Cardiac Arrest, 2010-2016..  JAMA network open.  2:-. 2019
204. Association Between Industry Payments to Physicians and Gabapentinoid Prescribing..  JAMA internal medicine.  179:1425-1428. 2019
205. Clinical Trial Evidence for the Real World..  JAMA internal medicine.  179:1333-1334. 2019
206. Evolution of Medicare Formulary Coverage Changes for Antithrombotic Therapies After Guideline Updates..  Circulation.  140:1227-1230. 2019
207. Evolution of the American College of Cardiology and American Heart Association Cardiology Clinical Practice Guidelines: A 10-Year Assessment..  Journal of the American Heart Association.  8:-. 2019
208. Claims-based cardiovascular outcome identification for clinical research: Results from 7 large randomized cardiovascular clinical trials..  American heart journal.  110-122. 2019
209. Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation..  The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.  47:393-395. 2019
210. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors..  Annals of internal medicine.  171:521-523. 2019
211. Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016..  JAMA network open.  2:-. 2019
212. The Bleeding Edge: Documenting Innovation and Injury in the Medical Device Industry..  JAMA.  322:190-192. 2019
213. Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015..  The Milbank quarterly.  97:796-819. 2019
214. Sharing of clinical trial data and results reporting practices among large pharmaceutical companies: cross sectional descriptive study and pilot of a tool to improve company practices..  BMJ (Clinical research ed.).  -. 2019
215. Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids..  Journal of general internal medicine.  34:1074-1076. 2019
216. Individual Patient-Level Data Sharing for Continuous Learning: A Strategy for Trial Data Sharing..  NAM perspectives.  2019
217. Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis..  BMC medicine.  17:-. 2019
218. Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals..  Circulation.  140:379-389. 2019
219. Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016..  The Journal of clinical endocrinology and metabolism.  104:2305-2314. 2019
220. Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults..  Journal of the American Geriatrics Society.  67:1571-1581. 2019
221. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments..  JAMA network open.  2:-. 2019
222. Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition..  JAMA internal medicine.  179:686-693. 2019
223. Communicating, and Justifying, Nonefficacy Benefits for New Drugs Approved on the Basis of Noninferiority Trials..  JAMA internal medicine.  179:721-722. 2019
224. Medicare Formulary Coverage and Restrictions for Opioid Potentiators from 2013 to 2017..  Journal of general internal medicine.  34:518-520. 2019
225. On the Need for (Only) High-Quality Clinical Practice Guidelines..  JAMA internal medicine.  179:-. 2019
226. Risk of Readmission After Discharge From Skilled Nursing Facilities Following Heart Failure Hospitalization: A Retrospective Cohort Study..  Journal of the American Medical Directors Association.  20:432-437. 2019
227. Timeliness of Postmarket Studies for New Pharmaceuticals Approved Between 2009 and 2012: a Cross-Sectional Analysis..  Journal of general internal medicine.  34:492-495. 2019
228. Kept in the dark: Scotland rejects "sunshine" legislation..  BMJ (Clinical research ed.).  -. 2019
229. Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation..  BMJ open.  9:-. 2019
230. U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015..  Preventive medicine.  123-129. 2019
231. Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing..  JAMA network open.  2:-. 2019
232. Association of Inferior Vena Cava Filter Use With Mortality Rates in Older Adults With Acute Pulmonary Embolism..  JAMA internal medicine.  179:263-265. 2019
233. Association of Statewide Certificate of Need Regulations With Percutaneous Coronary Intervention Appropriateness and Outcomes..  Journal of the American Heart Association.  8:-. 2019
234. Generic Drugs in the United States: Policies to Address Pricing and Competition..  Clinical pharmacology and therapeutics.  105:329-337. 2019
235. Coordinating Clinical Trials to Confirm Drug Safety and Efficacy-Resolving Uncertainty..  JAMA internal medicine.  179:-. 2019
236. Weighing the Harms and Benefits of Using Statins for Primary Prevention: Raising the Risk Threshold..  Annals of internal medicine.  170:62-63. 2018
237. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval..  Journal of managed care & specialty pharmacy.  24:1230-1238. 2018
238. Overview and experience of the YODA Project with clinical trial data sharing after 5 years..  Scientific data.  -. 2018
239. Breakthrough Therapy Designation for New Drugs-Reply..  JAMA.  320:2042-2043. 2018
240. Clinical Trials-We Get What We Pay For..  JAMA internal medicine.  178:-. 2018
241. Emergency Department Volume and Outcomes for Patients After Chest Pain Assessment..  Circulation. Cardiovascular quality and outcomes.  11:-. 2018
242. State-Level Population Estimates of Individuals Subject to and Not Meeting Proposed Medicaid Work Requirements..  JAMA internal medicine.  178:1552-1555. 2018
243. Registration, results reporting, and publication bias of clinical trials supporting FDA approval of neuropsychiatric drugs before and after FDAAA: a retrospective cohort study..  Trials.  19:-. 2018
244. Alirocumab's Price Reduction..  Circulation.  138:1502-1504. 2018
245. Evidence supporting FDA approval and CMS national coverage determinations for novel medical products, 2005 through 2016: A cross-sectional study..  Medicine.  97:-. 2018
246. Will research preprints improve healthcare for patients?.  BMJ (Clinical research ed.).  -. 2018
247. Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia: An Analysis of Within- and Between-Hospital Variation..  JAMA network open.  1:-. 2018
248. Review of clinical trial settings of drugs commonly used in primary care and approved between 2005 and 2012..  Journal of general internal medicine.  33:1431-1432. 2018
249. Adherence to the International Committee of Medical Journal Editors' (ICMJE) prospective registration policy and implications for outcome integrity: a cross-sectional analysis of trials published in high-impact specialty society journals..  Trials.  19:-. 2018
250. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials..  JAMA oncology.  4:-. 2018
251. Age of Data at the Time of Publication of Contemporary Clinical Trials..  JAMA network open.  1:-. 2018
252. Real-World Evidence: Promise and Peril For Medical Product Evaluation..  P & T : a peer-reviewed journal for formulary management.  43:464-472. 2018
253. Trends in opioid use in commercially insured and Medicare Advantage populations in 2007-16: retrospective cohort study..  BMJ (Clinical research ed.).  -. 2018
254. Medicare Beneficiary Out-of-Pocket Costs for Generic Cardiovascular Medications Available Through $4 Generic Drug Discount Programs..  Annals of internal medicine.  169:817-819. 2018
255. Accurate estimation of cardiovascular risk in a non-diabetic adult: detecting and correcting the error in the reported Framingham Risk Score for the Systolic Blood Pressure Intervention Trial population..  BMJ open.  8:-. 2018
256. Patterns and predictors of off-label prescription of psychiatric drugs..  PloS one.  13:-. 2018
257. Clinical Trial Evidence Supporting FDA Approval of Drugs Granted Breakthrough Therapy Designation..  JAMA.  320:301-303. 2018
258. Early Experiences With Journal Data Sharing Policies: A Survey of Published Clinical Trial Investigators..  Annals of internal medicine.  169:586-588. 2018
259. Off-label Use of Medications-Reply..  JAMA.  320:307-308. 2018
260. Disparities in the Use of Programmed Death 1 Immune Checkpoint Inhibitors..  The oncologist.  23:1388-1390. 2018
261. The Early Impact of Medicaid Expansion on Uninsured Patients Undergoing Emergency General Surgery..  The Journal of surgical research.  217-226. 2018
262. Older drugs with infantile evidence: the illustrative example of loop diuretics..  European heart journal. Quality of care & clinical outcomes.  4:232-234. 2018
263. Publication and Dissemination of Results in Clinical Trials of Neurology..  JAMA neurology.  75:890-891. 2018
264. The Impact of Off-Patent Drug Acquisitions on Prices..  Journal of general internal medicine.  33:1007-1009. 2018
265. The Open Translational Science in Schizophrenia (OPTICS) project: an open-science project bringing together Janssen clinical trial and NIMH data..  NPJ schizophrenia.  4:-. 2018
266. Quantifying the utilization of medical devices necessary to detect postmarket safety differences: A case study of implantable cardioverter defibrillators..  Pharmacoepidemiology and drug safety.  27:848-856. 2018
267. Fulfilling the Promise of Unique Device Identifiers..  Annals of internal medicine.  169:183-185. 2018
268. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs..  JAMA network open.  1:-. 2018
269. Network Optimization And The Continuity Of Physicians In Medicaid Managed Care..  Health affairs (Project Hope).  37:929-935. 2018
270. The US Food and Drug Administration's expedited approval programs: Addressing premarket flexibility with enhanced postmarket evidence generation..  Clinical trials (London, England).  15:243-246. 2018
271. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements..  Clinical trials (London, England).  15:219-229. 2018
272. Postmarket studies required by the US Food and Drug Administration for new drugs and biologics approved between 2009 and 2012: cross sectional analysis..  BMJ (Clinical research ed.).  -. 2018
273. Variation in the Diagnosis of Aspiration Pneumonia and Association with Hospital Pneumonia Outcomes..  Annals of the American Thoracic Society.  15:562-569. 2018
274. Factors Associated with Refugee Acute Healthcare Utilization in Southern Connecticut..  Journal of immigrant and minority health.  20:327-333. 2018
275. Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015..  JAMA internal medicine.  178:567-569. 2018
276. National Prescribing Trends for High-Risk Anticholinergic Medications in Older Adults..  Journal of the American Geriatrics Society.  66:1382-1387. 2018
277. Comparison of treatment effect sizes from pivotal and postapproval trials of novel therapeutics approved by the FDA based on surrogate markers of disease: a meta-epidemiological study..  BMC medicine.  16:-. 2018
278. Affordability and availability of off-patent drugs in the United States-the case for importing from abroad: observational study..  BMJ (Clinical research ed.).  -. 2018
279. Statewide Inferior Vena Cava Filter Placement, Complications, and Retrievals: Epidemiology and Recent Trends..  Medical care.  56:260-265. 2018
280. Gabapentin Approvals, Off-Label Use, and Lessons for Postmarketing Evaluation Efforts..  JAMA.  319:776-778. 2018
281. Direct-to-Consumer Broadcast Advertisements for Pharmaceuticals: Off-Label Promotion and Adherence to FDA Guidelines..  Journal of general internal medicine.  33:651-658. 2018
282. Factors Associated With Postmarketing Research for Approved Indications for Novel Medicines Approved by Both the FDA and EMA Between 2005 and 2010: A Multivariable Analysis..  Clinical pharmacology and therapeutics.  104:1000-1007. 2018
283. Defining Multiple Chronic Conditions for Quality Measurement..  Medical care.  56:193-201. 2018
284. Bringing Vioxx back to market..  BMJ (Clinical research ed.).  -. 2018
285. Biomedical journal speed and efficiency: a cross-sectional pilot survey of author experiences..  Research integrity and peer review.  -. 2018
286. Pediatric Exclusivity and Regulatory Authority: Implications of Amgen v HHS..  JAMA.  319:21-22. 2018
287. Physician Denial of Inappropriate Patient Requests-What If I Say No??.  JAMA internal medicine.  178:-. 2018
288. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study..  BMJ open.  7:-. 2017
289. Data Sharing and Cardiology: Platforms and Possibilities..  Journal of the American College of Cardiology.  70:3018-3025. 2017
290. New and incremental FDA black box warnings from 2008 to 2015..  Expert opinion on drug safety.  17:117-123. 2017
291. High Costs of FDA Approval for Formerly Unapproved Marketed Drugs..  JAMA.  318:2181-2182. 2017
292. Measuring clinical trial transparency: an empirical analysis of newly approved drugs and large pharmaceutical companies..  BMJ open.  7:-. 2017
293. Research, regulatory, and clinical decision-making: the importance of scientific integrity..  Journal of clinical epidemiology.  88-93. 2017
294. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study..  International journal of cancer.  142:414-423. 2017
295. Medicare Formulary Coverage Restrictions for Prescription Opioids, 2006 to 2015..  Annals of internal medicine.  167:895-896. 2017
296. Merits of Data Sharing: The Digitalis Investigation Group Trial..  Journal of the American College of Cardiology.  70:1825-1827. 2017
297. Quality of Care in the United States Territories, 1999-2012..  Medical care.  55:886-892. 2017
298. The FDA Unapproved Drugs Initiative: An Observational Study of the Consequences for Drug Prices and Shortages in the United States..  Journal of managed care & specialty pharmacy.  23:1066-1076. 2017
299. Age Differences in Hospital Mortality for Acute Myocardial Infarction: Implications for Hospital Profiling..  Annals of internal medicine.  167:555-564. 2017
300. Challenges to Biosimilar Substitution-Reply..  JAMA.  318:1186-1187. 2017
301. Opioid Prescribing for Opioid-Naive Patients in Emergency Departments and Other Settings: Characteristics of Prescriptions and Association With Long-Term Use..  Annals of emergency medicine.  71:326-336.e19. 2017
302. Trends in Omalizumab Utilization for Asthma: Evidence of Suboptimal Patient Selection..  The journal of allergy and clinical immunology. In practice.  6:1568-1577.e4. 2017
303. Characteristics of Novel Therapeutics and Postmarket Safety Events-Reply..  JAMA.  318:1067-1068. 2017
304. Hospital-Readmission Risk - Isolating Hospital Effects from Patient Effects..  The New England journal of medicine.  377:1055-1064. 2017
305. Association between FDA black box warnings and Medicare formulary coverage changes..  The American journal of managed care.  23:e310-e315. 2017
306. Inclusion of Demographic-Specific Information in Studies Supporting US Food & Drug Administration Approval of High-Risk Medical Devices..  JAMA internal medicine.  177:1390-1391. 2017
307. The Importance of Independent Evaluation..  JAMA internal medicine.  177:-. 2017
308. Can machine learning complement traditional medical device surveillance? A case study of dual-chamber implantable cardioverter-defibrillators..  Medical devices (Auckland, N.Z.).  165-188. 2017
309. US Food and Drug Administration Clearance of Moderate-Risk Otolaryngologic Devices via the 510(k) Process, 1997-2016..  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.  157:608-617. 2017
310. Facts Concerning Duexis Prescribing Habits Related to Combination Therapies-Reply..  JAMA internal medicine.  177:-. 2017
311. Characterizing expanded access and compassionate use programs for experimental drugs..  BMC research notes.  10:-. 2017
312. Association of Changing Hospital Readmission Rates With Mortality Rates After Hospital Discharge..  JAMA.  318:270-278. 2017
313. Association of the FDA Amendment Act with trial registration, publication, and outcome reporting..  Trials.  18:-. 2017
314. Trends in readmission rates for safety net hospitals and non-safety net hospitals in the era of the US Hospital Readmission Reduction Program: a retrospective time series analysis using Medicare administrative claims data from 2008 to 2015..  BMJ open.  7:-. 2017
315. The Need to Test Strategies Based on Common Sense..  JAMA internal medicine.  177:-. 2017
316. Regulatory Review of New Therapeutic Agents..  The New England journal of medicine.  376:-. 2017
317. Obstacles to the Adoption of Biosimilars for Chronic Diseases..  JAMA.  317:2163-2164. 2017
318. Having Their Cake and Eating It Too: Physician Skepticism of the Open Payments Program..  The American journal of bioethics : AJOB.  17:19-22. 2017
319. Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015..  Ophthalmology.  124:1237-1246. 2017
320. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010..  JAMA.  317:1854-1863. 2017
321. Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review..  BMJ (Clinical research ed.).  -. 2017
322. US drug marketing: how does promotion correspond with health value?.  BMJ (Clinical research ed.).  -. 2017
323. Hospital Characteristics Associated With Risk-standardized Readmission Rates..  Medical care.  55:528-534. 2017
324. Regulatory Review of New Therapeutic Agents - FDA versus EMA, 2011-2015..  The New England journal of medicine.  376:1386-7. 2017
325. Health and Health Care Use Among Individuals at Risk to Lose Health Insurance With Repeal of the Affordable Care Act..  JAMA internal medicine.  177:590-593. 2017
326. Two Decades of Cardiovascular Trials With Primary Surrogate Endpoints: 1990-2011..  Journal of the American Heart Association.  6. 2017
327. High Prices for Drugs With Generic Alternatives: The Curious Case of Duexis..  JAMA internal medicine.  177:305-306. 2017
328. Comparison of two independent systematic reviews of trials of recombinant human bone morphogenetic protein-2 (rhBMP-2): the Yale Open Data Access Medtronic Project..  Systematic reviews.  6:-. 2017
329. Assessing the potential clinical impact of reciprocal drug approval legislation on access to novel therapeutics in the USA: a cohort study..  BMJ open.  7:-. 2017
330. Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005-2014..  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.  156:683-692. 2017
331. Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014..  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.  156:285-288. 2017
332. Medicare Formulary Changes After the 2013 American College of Cardiology/American Heart Association Cholesterol Guideline..  Journal of the American College of Cardiology.  69:244-246. 2017
333. Data Desert for Inferior Vena Caval Filters: Limited Evidence, Supervision, and Research..  JAMA cardiology.  2:3-4. 2017
334. Prioritization of Generic Drug Review-Reply..  JAMA internal medicine.  177:141-142. 2017
335. Association Between Hospital Penalty Status Under the Hospital Readmission Reduction Program and Readmission Rates for Target and Nontarget Conditions..  JAMA.  316:2647-2656. 2016
336. The Rising Price of Naloxone - Risks to Efforts to Stem Overdose Deaths..  The New England journal of medicine.  375:2213-2215. 2016
337. Hospital Use of Observation Stays: Cross-sectional Study of the Impact on Readmission Rates..  Medical care.  54:1070-1077. 2016
338. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients..  Ophthalmology.  124:352-358. 2016
339. Frequency and Importance of Incomplete Screening Fetal Anatomic Sonography in Pregnancy..  Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.  35:2665-2673. 2016
340. Authors' reply to Ramachandran..  BMJ (Clinical research ed.).  -. 2016
341. Commentary: Diagnostic devices in clinical trials have high stakes for patient care..  BMJ (Clinical research ed.).  -. 2016
342. Data sharing through an NIH central database repository: a cross-sectional survey of BioLINCC users..  BMJ open.  6:-. 2016
343. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013..  Diabetes care.  40:468-475. 2016
344. Clinical research data sharing: what an open science world means for researchers involved in evidence synthesis..  Systematic reviews.  5:-. 2016
345. A Nationwide Assessment of the Association of Smoking Bans and Cigarette Taxes With Hospitalizations for Acute Myocardial Infarction, Heart Failure, and Pneumonia..  Medical care research and review : MCRR.  74:687-704. 2016
346. Industry support of physician education in the USA..  Journal of epidemiology and community health.  71:213-216. 2016
347. Identifying Sociodemographic Characteristics Associated With Burden Among Caregivers of the Urban Homebound: The Importance of Racial and Relationship Differences..  Gerontology & geriatric medicine.  -. 2016
348. Generic Drug Approvals Since the 1984 Hatch-Waxman Act..  JAMA internal medicine.  176:1391-3. 2016
349. Why the Open Payments Program Is Likely to Provide Systematic and Transparent Data on Financial Relationships with Industry..  The American journal of medicine.  129:-. 2016
350. Association between payments from manufacturers of pharmaceuticals to physicians and regional prescribing: cross sectional ecological study..  BMJ (Clinical research ed.).  -. 2016
351. The updated AMSA scorecard of conflict-of-interest policies: a survey of U.S. medical schools..  BMC medical education.  16:-. 2016
352. Open Access Platforms for Sharing Clinical Trial Data..  JAMA.  316:-. 2016
353. Accounting For Patients' Socioeconomic Status Does Not Change Hospital Readmission Rates..  Health affairs (Project Hope).  35:1461-70. 2016
354. Declining Admission Rates And Thirty-Day Readmission Rates Positively Associated Even Though Patients Grew Sicker Over Time..  Health affairs (Project Hope).  35:1294-302. 2016
355. Intensive Treatment and Severe Hypoglycemia Among Adults With Type 2 Diabetes..  JAMA internal medicine.  176:969-78. 2016
356. Population Of US Practicing Psychiatrists Declined, 2003-13, Which May Help Explain Poor Access To Mental Health Care..  Health affairs (Project Hope).  35:1271-7. 2016
357. Adoption of new agents and changes in treatment patterns for hepatitis C: 2010-2014..  The American journal of managed care.  22:e224-32. 2016
358. Therapeutic Substitution-Should It Be Systematic or Automatic?.  JAMA internal medicine.  176:-. 2016
359. Triage, Copayments, and Emergency Department Visits..  JAMA internal medicine.  176:854-5. 2016
360. Impact of Hospitalization for Acute Myocardial Infarction on Adherence to Statins Among Older Adults..  Circulation. Cardiovascular quality and outcomes.  9:364-71. 2016
361. Long-Term Risk for Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator Implantation: An Observational Cohort Study..  Annals of internal medicine.  165:20-29. 2016
362. Despite Federal Legislation, Shortages Of Drugs Used In Acute Care Settings Remain Persistent And Prolonged..  Health affairs (Project Hope).  35:798-804. 2016
363. Risk-standardized Acute Admission Rates Among Patients With Diabetes and Heart Failure as a Measure of Quality of Accountable Care Organizations: Rationale, Methods, and Early Results..  Medical care.  54:528-37. 2016
364. The US Food and Drug Administration 515 Program Initiative: Addressing the Evidence Gap for Widely Used, High-Risk Cardiovascular Devices?.  JAMA cardiology.  1:117-8. 2016
365. Availability of Clinical Trial Data From Industry-Sponsored Cardiovascular Trials..  Journal of the American Heart Association.  5:-. 2016
366. Comparative Effectiveness of Generic Atorvastatin and Lipitor® in Patients Hospitalized with an Acute Coronary Syndrome..  Journal of the American Heart Association.  5:-. 2016
367. Participation of the elderly, women, and minorities in pivotal trials supporting 2011-2013 U.S. Food and Drug Administration approvals..  Trials.  -. 2016
368. Making Electronic Health Records Work Better for Patient Care..  JAMA internal medicine.  176:-. 2016
369. Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013: A Cross-sectional Study..  JAMA internal medicine.  176:551-2. 2016
370. Impact of laboratory cost display on resident attitudes and knowledge about costs..  Postgraduate medical journal.  92:592-6. 2016
371. Reply..  Gastroenterology.  150:1249-1251. 2016
372. Financial Ties Between Emergency Physicians and Industry: Insights From Open Payments Data..  Annals of emergency medicine.  68:153-158.e4. 2016
373. High-Deductible Health Plans and Higher-Value Decisions: A Mirage or Are We Just Not There Yet?.  JAMA internal medicine.  176:397-8. 2016
374. Preventive Care Quality of Medicare Accountable Care Organizations: Associations of Organizational Characteristics With Performance..  Medical care.  54:326-35. 2016
375. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers..  BMJ (Clinical research ed.).  -. 2016
376. Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia..  JAMA.  315:582-92. 2016
377. Making Data Submitted to the Food and Drug Administration More Visible..  JAMA internal medicine.  176:-. 2016
378. Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting..  Journal of clinical epidemiology.  100-7. 2016
379. Characterisation of trials where marketing purposes have been influential in study design: a descriptive study..  Trials.  -. 2016
380. Fibrinolytic therapy in hospitals without percutaneous coronary intervention capabilities in China from 2001 to 2011: China PEACE-retrospective AMI study..  European heart journal. Acute cardiovascular care.  6:232-243. 2016
381. Response to Letter Regarding Article, "Poorly Cited Articles in Peer-Reviewed Cardiovascular Journals from 1997 to 2007: Analysis of 5-Year Citation Rates"..  Circulation.  133:e23-4. 2016
382. HbA1c overtesting and overtreatment among US adults with controlled type 2 diabetes, 2001-13: observational population based study..  BMJ (Clinical research ed.).  -. 2015
383. No Time to Wait..  JAMA internal medicine.  175:-. 2015
384. US Federal Government Efforts to Improve Clinical Trial Transparency with Expanded Trial Registries and Open Data Sharing..  AMA journal of ethics.  17:1152-9. 2015
385. How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?.  Clinical orthopaedics and related research.  474:1053-68. 2015
386. Clinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012..  BMJ open.  5:-. 2015
387. Regulatory anticipation of postmarket safety problems for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study..  Pharmacoepidemiology and drug safety.  25:687-94. 2015
388. Global Drug Safety Insights From Taiwan..  JAMA internal medicine.  175:-. 2015
389. Would a Breakthrough Therapy by Any Other Name Be as Promising?.  JAMA internal medicine.  175:1858-9. 2015
390. Hospital-Based Acute Care After Total Hip and Knee Arthroplasty: Implications for Quality Measurement..  The Journal of arthroplasty.  31:573-8.e2. 2015
391. Predictors and outcomes of unplanned readmission to a different hospital..  International journal for quality in health care : journal of the International Society for Quality in Health Care.  27:513-9. 2015
392. Regulatory watch: Characterizing the US FDA's approach to promoting transformative innovation..  Nature reviews. Drug discovery.  14:740-1. 2015
393. On Ghosts and Other Unwelcome Guests..  Journal of general internal medicine.  30:1389-91. 2015
394. Revisiting Essure--Toward Safe and Effective Sterilization..  The New England journal of medicine.  373:-. 2015
395. FDA Policy and Cardiovascular Medicine..  Circulation.  132:1136-45. 2015
396. Informed Consent and Communicating Risk and Benefits of Research on Higher-Risk Medications..  JAMA internal medicine.  175:-. 2015
397. Promoting Evidence-Based High-Value Health Care..  JAMA internal medicine.  175:-. 2015
398. Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011..  JAMA.  314:604-12. 2015
399. Physician and other healthcare personnel responses to hospital stroke quality of care performance feedback: a qualitative study..  BMJ quality & safety.  25:441-7. 2015
400. Strengthening Medical Device Postmarket Safety Surveillance..  JAMA internal medicine.  175:1350-1. 2015
401. Development and Validation of an Algorithm to Identify Planned Readmissions From Claims Data..  Journal of hospital medicine.  10:670-7. 2015
402. On Chlorofluorocarbon Bans and Inhaled Albuterol Prices..  JAMA internal medicine.  175:-. 2015
403. National quality assessment evaluating spironolactone use during hospitalization for acute myocardial infarction (AMI) in China: China Patient-centered Evaluation Assessment of Cardiac Events (PEACE)-Retrospective AMI Study, 2001, 2006, and 2011..  Journal of the American Heart Association.  4:-. 2015
404. Postmarket Modifications of High-Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration..  Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.  153:400-8. 2015
405. High-risk medical devices: why do we not better understand effectiveness and safety?.  JAMA internal medicine.  175:939-40. 2015
406. Regulatory review time and post-market safety events for novel medicines approved by the EMA between 2001 and 2010: a cross-sectional study..  British journal of clinical pharmacology.  80:716-26. 2015
407. Post-market clinical research conducted by medical device manufacturers: a cross-sectional survey..  Medical devices (Auckland, N.Z.).  241-9. 2015
408. National assessment of early β-blocker therapy in patients with acute myocardial infarction in China, 2001-2011: The China Patient-centered Evaluative Assessment of Cardiac Events (PEACE)-Retrospective AMI Study..  American heart journal.  170:506-15.e1. 2015
409. Trial-results reporting and academic medical centers..  The New England journal of medicine.  372:2371-2. 2015
410. A better pain plan..  JAMA internal medicine.  175:-. 2015
411. Regional-Level Correlations in Inappropriate Imaging Rates for Prostate and Breast Cancers: Potential Implications for the Choosing Wisely Campaign..  JAMA oncology.  1:185-94. 2015
412. Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugs..  Health affairs (Project Hope).  34:681-8. 2015
413. Observation encounters and subsequent nursing facility stays..  The American journal of managed care.  21:e276-81. 2015
414. Older women with localized breast cancer: costs and survival rates increased across two time periods..  Health affairs (Project Hope).  34:592-600. 2015
415. Poorly cited articles in peer-reviewed cardiovascular journals from 1997 to 2007: analysis of 5-year citation rates..  Circulation.  131:1755-62. 2015
416. Reporting of noninferiority trials in ClinicalTrials.gov and corresponding publications..  JAMA.  313:1163-5. 2015
417. Potential overtreatment of diabetes mellitus in older adults with tight glycemic control..  JAMA internal medicine.  175:356-62. 2015
418. Variation in US hospital emergency department admission rates by clinical condition..  Medical care.  53:237-44. 2015
419. Patterns of use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers among patients with acute myocardial infarction in China from 2001 to 2011: China PEACE-Retrospective AMI Study..  Journal of the American Heart Association.  4. 2015
420. Association of hospital volume with readmission rates: a retrospective cross-sectional study..  BMJ (Clinical research ed.).  -. 2015
421. Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study..  BMJ (Clinical research ed.).  -. 2015
422. Confronting bias..  JAMA internal medicine.  175:-. 2015
423. We can see the (risks of UV) light..  JAMA internal medicine.  175:311-2. 2015
424. Decision-making and cancer screening: a qualitative study of older adults with multiple chronic conditions..  Journal of geriatric oncology.  6:93-100. 2014
425. The shape of things to come: 3D printing in medicine..  JAMA.  312:2213-4. 2014
426. Attitudes of hospital leaders toward publicly reported measures of health care quality..  JAMA internal medicine.  174:1904-11. 2014
427. Development and use of an administrative claims measure for profiling hospital-wide performance on 30-day unplanned readmission..  Annals of internal medicine.  161:S66-75. 2014
428. Reporting discrepancies between the clinicaltrials.gov results database and peer-reviewed publications..  Annals of internal medicine.  161:-. 2014
429. Marketing to physicians in a digital world..  The New England journal of medicine.  371:1857-9. 2014
430. Payments for acute myocardial infarction episodes-of-care initiated at hospitals with and without interventional capabilities..  Circulation. Cardiovascular quality and outcomes.  7:882-8. 2014
431. Rate of asthma trial outcomes reporting on ClinicalTrials.gov and in the published literature..  The Journal of allergy and clinical immunology.  134:1443-1446. 2014
432. Inconsistencies among European Union pharmaceutical regulator safety communications: a cross-country comparison..  PloS one.  9:-. 2014
433. Pediatric screening urinalysis: a difference-in-differences analysis of how a 2007 change in guidelines impacted use..  BMC pediatrics.  -. 2014
434. Predictors of clinical trial data sharing: exploratory analysis of a cross-sectional survey..  Trials.  -. 2014
435. It's not just about the money, money, money…..  JAMA internal medicine.  174:-. 2014
436. Randomized clinical trials and observational studies are more often alike than unlike..  JAMA internal medicine.  174:-. 2014
437. Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional study..  JAMA internal medicine.  174:1518-20. 2014
438. Trends in use of ezetimibe after the ENHANCE trial, 2007 through 2010..  JAMA internal medicine.  174:1486-93. 2014
439. Restricting interactions with industry to promote evidence-based prescribing..  JAMA internal medicine.  174:-. 2014
440. Place of residence and outcomes of patients with heart failure: analysis from the telemonitoring to improve heart failure outcomes trial..  Circulation. Cardiovascular quality and outcomes.  7:749-56. 2014
441. Evolution of breast cancer screening in the Medicare population: clinical and economic implications..  Journal of the National Cancer Institute.  106. 2014
442. Descriptions and interpretations of the ACCORD-Lipid trial in the news and biomedical literature: a cross-sectional analysis..  JAMA internal medicine.  174:1176-82. 2014
443. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011..  JAMA internal medicine.  174:1116-24. 2014
444. Sea change in open science and data sharing: leadership by industry..  Circulation. Cardiovascular quality and outcomes.  7:499-504. 2014
445. Withdrawal of Personal Genome Service--reply..  JAMA.  311:2441-2. 2014
446. National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010..  American heart journal.  169:78-85.e4. 2014
447. Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010..  JAMA.  311:2331-3. 2014
448. Impact of drug policy on regional trends in ezetimibe use..  Circulation. Cardiovascular quality and outcomes.  7:589-96. 2014
449. High incarceration rates among black men enrolled in clinical studies may compromise ability to identify disparities..  Health affairs (Project Hope).  33:848-55. 2014
450. Trial evidence and approval of therapeutic agents--reply..  JAMA.  311:-. 2014
451. Physician clinical management strategies and reasoning: a cross-sectional survey using clinical vignettes of eight common medical admissions..  BMC health services research.  -. 2014
452. Moving forward from rhBMP-2: open science and data sharing..  Spine.  39:531-2. 2014
453. Hospital variation in risk-standardized hospital admission rates from US EDs among adults..  The American journal of emergency medicine.  32:837-43. 2014
454. Reporting of results in ClinicalTrials.gov and high-impact journals..  JAMA.  311:1063-5. 2014
455. Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada..  American heart journal.  167:683-9. 2014
456. Association of physician specialty and medical therapy for benign prostatic hyperplasia..  Medical care.  52:128-36. 2014
457. Transfer rates from nonprocedure hospitals after initial admission and outcomes among elderly patients with acute myocardial infarction..  JAMA internal medicine.  174:213-22. 2014
458. Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012..  JAMA.  311:368-77. 2014
459. For-profit hospital ownership status and use of brachytherapy after breast-conserving surgery..  Surgery.  155:776-88. 2013
460. Hospital-based, acute care after ambulatory surgery center discharge..  Surgery.  155:743-53. 2013
461. Hospital readmission performance and patterns of readmission: retrospective cohort study of Medicare admissions..  BMJ (Clinical research ed.).  -. 2013
462. The cost implications of prostate cancer screening in the Medicare population..  Cancer.  120:96-102. 2013
463. Prescription-drug coupons--no such thing as a free lunch..  The New England journal of medicine.  369:1188-9. 2013
464. Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer..  Breast cancer research and treatment.  141:155-63. 2013
465. Age-based and sex-based disparities in screening colonoscopy use among medicare beneficiaries..  Journal of clinical gastroenterology.  47:630-6. 2013
466. Direct-to-consumer television advertising: time to turn off the tube?.  Journal of general internal medicine.  28:862-4. 2013
467. A historic moment for open science: the Yale University Open Data Access project and medtronic..  Annals of internal medicine.  158:910-1. 2013
468. Evaluation of the Mobile Acute Care of the Elderly (MACE) service..  JAMA internal medicine.  173:990-6. 2013
469. Hospital-based, acute care use among patients within 30 days of discharge after coronary artery bypass surgery..  The Annals of thoracic surgery.  96:96-104. 2013
470. Regional density of cardiologists and rates of mortality for acute myocardial infarction and heart failure..  Circulation. Cardiovascular quality and outcomes.  6:352-9. 2013
471. Time to publication among completed clinical trials..  JAMA internal medicine.  173:825-8. 2013
472. Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia..  JAMA.  309:587-93. 2013
473. The cost of breast cancer screening in the Medicare population..  JAMA internal medicine.  173:220-6. 2013
474. Medical school gift restriction policies and physician prescribing of newly marketed psychotropic medications: difference-in-differences analysis..  BMJ (Clinical research ed.).  -. 2013
475. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia..  JAMA.  309:355-63. 2013
476. Use of hospital-based acute care among patients recently discharged from the hospital..  JAMA.  309:364-71. 2013
477. Sharing of clinical trial data among trialists: a cross sectional survey..  BMJ (Clinical research ed.).  -. 2012
478. Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries..  Archives of internal medicine.  172:1601-3. 2012
479. Discharge disposition disagreements and re-admission risk among older adults: a retrospective cohort study..  BMJ open.  2. 2012
480. Financial stress and outcomes after acute myocardial infarction..  PloS one.  7:-. 2012
481. Visits for primary care services to primary care and specialty care physicians, 1999 and 2007..  Archives of internal medicine.  172:1421-3. 2012
482. Based on key measures, care quality for Medicare enrollees at safety-net and non-safety-net hospitals was almost equal..  Health affairs (Project Hope).  31:1739-48. 2012
483. Association of chronic diseases and impairments with disability in older adults: a decade of change?.  Medical care.  50:501-7. 2012
484. Regulatory review of novel therapeutics--comparison of three regulatory agencies..  The New England journal of medicine.  366:2284-93. 2012
485. Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise..  Archives of internal medicine.  172:724-30. 2012
486. Association between physician quality improvement incentives and ambulatory quality measures..  The American journal of managed care.  18:e126-34. 2012
487. Coronary artery bypass graft: contemporary heart surgery center performance in China..  Circulation. Cardiovascular quality and outcomes.  5:214-21. 2012
488. The importance of clinical trial data sharing: toward more open science..  Circulation. Cardiovascular quality and outcomes.  5:238-40. 2012
489. "Transparency reports" on industry payments to physicians and teaching hospitals..  JAMA.  307:1029-30. 2012
490. Impact of state laws that extend eligibility for parents' health insurance coverage to young adults..  Pediatrics.  129:426-32. 2012
491. Ghostwriting: research misconduct, plagiarism, or fool's gold?.  The American journal of medicine.  125:324-6. 2012
492. Comparison of hospital risk-standardized mortality rates calculated by using in-hospital and 30-day models: an observational study with implications for hospital profiling..  Annals of internal medicine.  156:19-26. 2012
493. Publication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysis..  BMJ (Clinical research ed.).  -. 2012
494. Skilled nursing facility referral and hospital readmission rates after heart failure or myocardial infarction..  The American journal of medicine.  125:100.e1-9. 2012
495. State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning..  Health affairs (Project Hope).  31:188-98. 2012
496. The use and misuse of thrombolytic therapy within the Veterans Health Administration..  Medical care.  50:66-73. 2012
497. Generic atorvastatin and health care costs..  The New England journal of medicine.  366:201-4. 2011
498. Estimating and reporting on the quality of inpatient stroke care by Veterans Health Administration Medical Centers..  Circulation. Cardiovascular quality and outcomes.  5:44-51. 2011
499. US cardiologist workforce from 1995 to 2007: modest growth, lasting geographic maldistribution especially in rural areas..  Health affairs (Project Hope).  30:2301-9. 2011
500. Promoting transparency in pharmaceutical industry-sponsored research..  American journal of public health.  102:72-80. 2011
501. A model for dissemination and independent analysis of industry data..  JAMA.  306:1593-4. 2011
502. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study..  BMJ (Clinical research ed.).  -. 2011
503. Recent trends in chronic disease, impairment and disability among older adults in the United States..  BMC geriatrics.  -. 2011
504. Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing..  PloS one.  6:-. 2011
505. Assessing the impact of screening colonoscopy on mortality in the medicare population..  Journal of general internal medicine.  26:1441-9. 2011
506. Correlation of inpatient and outpatient measures of stroke care quality within veterans health administration hospitals..  Stroke.  42:2269-75. 2011
507. Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial..  Archives of internal medicine.  171:1100-7. 2011
508. Prevalence of inadequate blood pressure control among veterans after acute ischemic stroke hospitalization: a retrospective cohort..  Circulation. Cardiovascular quality and outcomes.  4:399-407. 2011
509. Do imaging studies performed in physician offices increase downstream utilization?: an empiric analysis of cardiac stress testing with imaging..  JACC. Cardiovascular imaging.  4:630-7. 2011
510. Advanced access scheduling outcomes: a systematic review..  Archives of internal medicine.  171:1150-9. 2011
511. Use of fibrates in the United States and Canada..  JAMA.  305:1217-24. 2011
512. Switching from rosiglitazone: thinking outside the class..  JAMA.  305:820-1. 2011
513. Audit and feedback: an intervention to improve discharge summary completion..  Journal of hospital medicine.  6:28-32. 2011
514. Expanding the frontier of outcomes measurement for public reporting..  Circulation. Cardiovascular quality and outcomes.  4:11-3. 2011
515. Persistence of cardiovascular risk after rofecoxib discontinuation..  Archives of internal medicine.  170:2035-6. 2010
516. State-sponsored public reporting of hospital quality: results are hard to find and lack uniformity..  Health affairs (Project Hope).  29:2317-22. 2010
517. Who is missing from the measures? Trends in the proportion and treatment of patients potentially excluded from publicly reported quality measures..  American heart journal.  160:943-950.e1-5. 2010
518. Scheduled and unscheduled hospital readmissions among patients with diabetes..  The American journal of managed care.  16:760-7. 2010
519. National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release..  Circulation. Cardiovascular quality and outcomes.  3:459-67. 2010
520. Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis..  Journal of the American College of Cardiology.  56:702-11. 2010
521. Beyond insurance coverage: usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey..  American heart journal.  160:115-21. 2010
522. Use of administrative claims models to assess 30-day mortality among Veterans Health Administration hospitals..  Medical care.  48:652-8. 2010
523. Laboratory test ordering at physician offices with and without on-site laboratories..  Journal of general internal medicine.  25:1057-63. 2010
524. Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006..  JAMA.  303:2141-7. 2010
525. Physician attitudes toward industry: a view across the specialties..  Archives of surgery (Chicago, Ill. : 1960).  145:570-7. 2010
526. Health care insurance, financial concerns in accessing care, and delays to hospital presentation in acute myocardial infarction..  JAMA.  303:1392-400. 2010
527. A random effects multinomial logit analysis of using Medicare and VA healthcare among veterans with dementia..  Home health care services quarterly.  29:91-104. 2010
528. Hospital volume and 30-day mortality for three common medical conditions..  The New England journal of medicine.  362:1110-8. 2010
529. Differences in patient survival after acute myocardial infarction by hospital capability of performing percutaneous coronary intervention: implications for regionalization..  Archives of internal medicine.  170:433-9. 2010
530. The physical activity contract--tailored to promote physical activity in a geriatric outpatient setting: a pilot study..  Journal of the American Geriatrics Society.  58:604-6. 2010
531. Conflicts of interest, authorship, and disclosures in industry-related scientific publications..  Mayo Clinic proceedings.  85:199-200; author reply 201-4. 2010
532. The relationship between systolic blood pressure on admission and mortality in older patients with heart failure..  European journal of heart failure.  12:148-55. 2010
533. Self-reported and actual beta-blocker prescribing for heart failure patients: physician predictors..  PloS one.  4:-. 2009
534. Determinants of cardiac catheterization use in older Medicare patients with acute myocardial infarction..  Circulation. Cardiovascular quality and outcomes.  3:54-62. 2009
535. Economic evaluation of a comprehensive teenage pregnancy prevention program: pilot program..  American journal of preventive medicine.  37:S280-7. 2009
536. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance..  Archives of internal medicine.  169:1976-85. 2009
537. Recent national trends in readmission rates after heart failure hospitalization..  Circulation. Heart failure.  3:97-103. 2009
538. Health care choices and decisions in the United States and Canada..  JAMA.  302:1803-4. 2009
539. Appropriateness of collaborations between industry and the medical profession: physicians' perceptions..  The American journal of medicine.  122:955-60. 2009
540. Mis-SHAPEing public health policy..  Circulation. Cardiovascular quality and outcomes.  2:681-3. 2009
541. Trial publication after registration in ClinicalTrials.Gov: a cross-sectional analysis..  PLoS medicine.  6:-. 2009
542. Exposure to low-dose ionizing radiation from medical imaging procedures..  The New England journal of medicine.  361:849-57. 2009
543. Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006..  JAMA.  302:767-73. 2009
544. Use of Medicare and Department of Veterans Affairs health care by veterans with dementia: a longitudinal analysis..  Journal of the American Geriatrics Society.  57:1908-14. 2009
545. Cognitive decline among patients with chronic obstructive pulmonary disease..  American journal of respiratory and critical care medicine.  180:134-7. 2009
546. Use of stroke secondary prevention services: are there disparities in care?.  Stroke.  40:1811-9. 2009
547. Policy research: using evidence to improve healthcare delivery systems..  Circulation.  119:891-8. 2009
548. Relationships with the drug industry: More regulation, greater transparency..  BMJ (Clinical research ed.).  -. 2009
549. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure..  Circulation. Cardiovascular quality and outcomes.  1:29-37. 2008
550. Appropriate proton pump inhibitor use among older adults: a retrospective chart review..  The American journal of geriatric pharmacotherapy.  6:249-54. 2008
551. Comparison of the US and Canadian health care systems: a tale of 2 Mount Sinai's..  JAMA.  300:1934-6. 2008
552. Dual use of Veterans Affairs services and use of recommended ambulatory care..  Medical care.  46:309-16. 2008
553. Electronic health record components and the quality of care..  Medical care.  46:1267-72. 2008
554. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation..  JAMA.  299:1800-12. 2008
555. Hospital remoteness and thirty-day mortality from three serious conditions..  Health affairs (Project Hope).  27:1707-17. 2008
556. Influence of patients' socioeconomic status on clinical management decisions: a qualitative study..  Annals of family medicine.  6:53-9. 2008
557. Pharmaceutical industry marketing: understanding its impact on women's health..  Obstetrical & gynecological survey.  63:585-96. 2008
558. Racial and ethnic differences in personal cervical cancer screening amongst post-graduate physicians: results from a cross-sectional survey..  BMC public health.  -. 2008
559. Regional variation in cardiac catheterization appropriateness and baseline risk after acute myocardial infarction..  Journal of the American College of Cardiology.  51:716-23. 2008
560. Statistical models and patient predictors of readmission for heart failure: a systematic review..  Archives of internal medicine.  168:1371-86. 2008
561. The ADVANTAGE seeding trial: a review of internal documents..  Annals of internal medicine.  149:251-8. 2008
562. Updated estimates of pharmaceutical company payments to physicians in Vermont..  JAMA.  300:1998-2000. 2008
563. Use of ezetimibe in the United States and Canada..  The New England journal of medicine.  358:1819-28. 2008
564. Use of recommended ambulatory care services: is the Veterans Affairs quality gap narrowing?.  Archives of internal medicine.  168:950-8. 2008
565. Pharmaceutical company payments to physicians: early experiences with disclosure laws in Vermont and Minnesota..  JAMA.  297:1216-23. 2007
566. Acute myocardial infarction and congestive heart failure outcomes at specialty cardiac hospitals..  Circulation.  116:2280-7. 2007
567. Cardiac Certificate of Need regulations and the availability and use of revascularization services..  American heart journal.  154:767-75. 2007
568. Certificate of need regulation and cardiac catheterization appropriateness after acute myocardial infarction..  Circulation.  115:1012-9. 2007
569. Insurance coverage and care of patients with non ST-segment elevation acute coronary syndromes..  Annals of internal medicine.  147:-. 2007
570. Is P4P really FFS?.  JAMA.  298:1797-9. 2007
571. Quality of care for acute myocardial infarction at urban safety-net hospitals..  Health affairs (Project Hope).  26:238-48. 2007
572. The importance of population-based performance measures..  Health services research.  42:1-6. 2007
573. Use of preventive care by elderly male veterans receiving care through the Veterans Health Administration, Medicare fee-for-service, and Medicare HMO plans..  American journal of public health.  97:2179-85. 2007
574. What have we learnt from Vioxx?.  BMJ (Clinical research ed.).  334:120-3. 2007
575. What is different about the market for health care?.  JAMA.  298:2785-7. 2007
576. Effect of blinded peer review on abstract acceptance..  JAMA.  295:1675-80. 2006
577. Brief report: Housestaff adherence to cervical cancer screening recommendations..  Journal of general internal medicine.  21:68-70. 2006
578. Description of a research-based health activism curriculum for medical students..  Journal of general internal medicine.  21:1325-8. 2006
579. Refusal of care by patients..  JAMA.  296:-. 2006
580. Use of health care services by lower-income and higher-income uninsured adults..  JAMA.  295:2027-36. 2006
581. Use of preventive care by the working poor in the United States..  Preventive medicine.  44:254-9. 2006
582. Mismeasurement and the resonance of strong confounders: correlated errors..  American journal of epidemiology.  150:88-96. 1999